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ABSTRACT
In the last decade polycistronic vectors have
become essential tools for both basic science and
gene therapy applications. In order to co-express
heterologous polypeptides, different systems have
been developed from Internal Ribosome Entry Site
(IRES) based vectors to the use of the 2A peptide.
Unfortunately, these methods are not fully suitable
for the efficient and reproducible modulation of the
ratio between the proteins of interest. Here we
describe a novel bicistronic vector type based on
the use of alternative splicing. By modifying the
consensus sequence that governs splicing, we
demonstrate that the ratio between the synthesized
proteins could easily vary from 1:10 to 10:1.
We have established this system with luciferase
genes and we extended its application to the
production of recombinant monoclonal antibodies.
We have shown that these vectors could be used
in several typical cell lines with similar efficiencies.
We also present an adaptation of these vectors to
hybrid alternative splicing/IRES constructs that
allow a ratio-controlled expression of proteins of
interest in stably transfected cell lines.
INTRODUCTION
Many applications require co-expression of heterologous
polypeptides from basic research to gene therapy experi-
ments. In this purpose, numerous approaches have been
developed from co-transfection with two independent
constructs to single vectors where co-expression is
achieved through the use of several promoters, Internal
Ribosome Entry Sites (IRES) or Foot-and-Mouth
Disease-Virus (FMDV)-derived 2A peptides (1). All
these strategies have various drawbacks but one particular
disadvantage is that they do not allow easy, reproducible
and great modulation of the expression ratio between
the proteins of interest. However, in several cases, this
property might be useful.
One particular example is the production of recom-
binant antibodies, which are formed by association of
two light chains (LCs) and two heavy chains (HCs).
Studies demonstrated that intracellular HC:LC ratio is
of major importance regarding antibodies production
eﬃciency (2,3). The optimum ratio for eﬃcient production
depends on many factors including the cell type used for
expression, and whether production is performed in a
transient or stable context (4,5). Therefore, this ratio has
to be adaptable to allow optimal antibody production in
any case.
The system described in this article is based on
alternative splicing to ensure regulated co-expression of
two polypeptides. Alternative splicing is the mechanism
by which diﬀerent mature mRNAs can be generated
from one pre-mRNA through the use of alternative
splice sites (6). Splice sites deﬁne the border of an intron
and consist of the almost invariant GU dinucleotide,
called 50 splice site (50SS) and the 30 splice site (30SS)
that comprises three sequence elements: the branch
point, followed by a polypyrimidine tract, and the
terminal AG sequence. Both 50SS and 30SS are comprised
within larger, less conserved consensus regions. Choice
between alternative splice sites is regulated in many ways
including the inherent strength of the splice sites, i.e. how
close they are from the consensus sequences (7) and the
presence of cis-regulating elements in the surrounding
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or Silencers (ESS) (8).
In the present study we tried to evaluate if alternative
splicing could be a valuable mechanism to co-express two
proteins in a regulated manner through the mutation
of splice sites. The system was tested for diﬀerent
applications including multimeric proteins expression, in
various cell types and both in a transient or stable context.
MATERIAL AND METHODS
Plasmid construction
The vector’s backbone was obtained from pCRFL
previously described (9) containing the chimeric intron of
pRL-CMV (Promega). Luc R was polymerase chain
reaction (PCR) ampliﬁed from pRL-CMV (Promega)
using HA-LucR -F and -R primers (primer sequences are
available in Supplementary Data and Table S1). Primers
contained the following restriction sites: AvrII/BamHI
(forward primer) and PacI/SacII/NotI (reverse primer).
The reverse primer included the sequence of a second
30SS consisting in the following elements: branch point,
pyrimidine tract and acceptor splice site sequence. These
elements were included between the PacI and NotI
restriction sites. Luc F was ampliﬁed from pGL3
(Promega) using HA-LucF -F and -R primers, containing
PacI/NheI and BglII/EcoRV sites. The forward primers,
used to amplify both fragments, contained the sequence
coding the hemaglutinin (HA) tag in fusion with the
luciferase open reading frames. Both PCR fragments
were respectively digested with AvrII/PacI and PacI/
BglII and cloned into the XbaI/BglII digested pCRFL.
Three putative alternative translation initiation codons
CTG present in the vector 50-UTR were mutated into
TTG sequences using the Quikchange XL site directed
mutagenesis kit (Stratagene) with oligonucleotides CTG-
mut1 to CTG-mut3 -F and -R designed according to the
manufacturer’s instructions. The resulting plasmid, further
called pV1, was checked by sequence analysis. Plasmid
expressing the LCs and HCs of the anti-N-VEGF
antibody further called pA1, was obtained by replacing
HA-LucR and HA-LucF coding cistrons of pV1 by the
PCR ampliﬁed LCs and HCs respectively using BamHI/
XbaI and NheI/EcoRV restriction sites. The sequences of
the LCs and HCs were PCR ampliﬁed with the LC -F/-R
and HC -F/-R primers from two plasmids previously
constructed and containing the sequences of each chain
isolated from the hybridoma cDNA.
EMCV IRES and EF-1a promoter were PCR ampliﬁed
from pCREL (9) and pCREF1L (10) with primers
(EMCV -F/-R and EF1a -F/-R) inserting SacII (50-end)
and NheI (30-end) restriction sites. The resulting fragments
were digested with SacII/NheI and used in a tri-molecular
ligation with fragments resulting from XhoI/SacII and
NheI/XhoI digestion of pA1 thus replacing the 30SS
between the cistrons by the IRES (pCI) or the EF-1a
promoter (pCE).
For stable transfection experiments, a cassette
containing the VEGF-IRES-A and the neomycin coding
sequence was inserted downstream of the HC ORF. Both
elements were PCR ampliﬁed from pCRA121mSpHA (11)
and pCDNA3 (Invitrogen), with primers IRES-VEGF-F/
overlap-R and overlap-F/Neo-R, then overlapped.
Further cloning of this cassette was performed using the
EcoRV/BglII digested fragment in a tri-molecular ligation
with BglII/PvuI and PvuI/EcoRV digested fragments of
diﬀerent plasmids: pA1, mutants pA2 to pA9 (described
below), pCI and pCE. Resulting plasmids were called
pAx-s, pCI-s and pCE-s.
Construction of mutants for the 30SS
Degenerated oligonucleotides mut-V1-F and mut V1-R
were used to create mutants on three bases of the second
30SS in the pV1 vector. Equimolar amounts of each
oligonucleotide were mixed and hybridized, leading to
a short double stranded DNA fragment with cohesive 50-
and 30-ends corresponding to sequences for NotI and PacI
restriction sites. Diﬀerent dilutions of the hybridization
product were cloned into the NotI/PacI digested pV1.
More than 200 clones were analyzed and DNA sequences
were determined (Millegen sequencing services) in order to
isolate diﬀerent mutants for the second acceptor splice
site. Eight mutants, called pV2 to pV9, were chosen for
further experiments.
Construction of the ﬁrst 30SS mutants was performed by
inserting point mutations in pA1 using the Quikchange
XL site directed mutagenesis kit (Stratagene) according
to the manufacturer’s instructions with the primers
couples listed from MUT-A2 -F/-R to MUT-A9 -F/-R.
Resulting plasmids were called pA2 to pA9.
Cell culture and transfection
CHO cells (ATCC CCL61) were cultivated in EMEM
medium (Gibco), HeLa (ATCC CCL2) and NIH-3T3
(ATCC CRL-1658) cells in DMEM containing 1g/l
glucose (Gibco) and HEK 293T cells (GenHunter, Q401)
in DMEM containing 4.5g/l glucose (Gibco). All media
were supplemented with 10% FCS, 1% glutamine and
antibiotics. All cell types were cultivated at 37 Ci na
humidiﬁed 5% CO2 atmosphere. For transient trans-
fection experiments, cells were seeded either onto six-
well dishes or 10cm plates 24h prior to transfection.
CHO cells were transfected with Fugene-6 transfection
reagent (Roche) according to the manufacturer’s
instructions. HeLa, NIH-3T3 and HEK293T cells were
transfected using the JetPEI transfection reagent
(Polyplus Transfection) according to the manufacturer’s
instructions. For stable transfection, CHO cells were
transfected as described earlier with plasmids pAx-s,
pCI-s and pCE-s and treated with 0.75mg/ml G418
(Euromedex) 48h after transfection. Surviving cells were
pooled and ampliﬁed for 25 more days with continuous
G418 selection.
Western blotanalysis
Twenty four hours after transfection, cells were collected
and sonicated in 50ml of sodium dodecylsulfate (SDS)
sample buﬀer. Protein concentration in the cell lysates
was determined using the bicinchoninic acid method
(Interchim). Samples were boiled at 95 C for 5min after
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were separated on a NuPAGE 4–12% Bis-Tris gel
(Invitrogen). After electrophoretic transfer, the nitro-
cellulose membranes (Schleicher & Schu ¨ ell) were blocked
with 3% skimmed milk. Tagged luciferases were immuno-
detected using mouse monoclonal anti-HA (dilution
1:1000) (Babco) as a primary antibody and peroxidase-
conjugated sheep anti-mouse (dilution 1:10000)
(Amersham) as a secondary antibody and the ECL
detection kit (Amersham). HCs and LCs of the anti-N-
VEGF antibody were detected using a peroxidase-
conjugated sheep anti-mouse IgG antibody (dilution
1:2500) (Promega). Normalization was done using a
monoclonal anti b-actin antibody (dilution 1:10000)
(Sigma-Aldrich). Densitometric analysis was performed
using Scion Image 1.63 software (Scion Corporation).
Total and polysomal RNA isolation and RT–PCR analysis
Sucrose gradient fractionation was performed essentially
as described earlier (12). Cell extracts were prepared
by lysis at 4 C in extraction buﬀer (10mM Tris–HCl,
pH 8.0, 140mM NaCl, 1.5mM MgCl2, 0.5% Nonidet-
P40 and 500U/ml RNAsin), and nuclei were removed
by centrifugation (12000g,1 0 s ,4  C). The supernatant
was supplemented with 20mM dithiothreitol, 150mg/ml
cycloheximide, 665mg/ml heparin and 1mM phenyl-
methylsulfonyl ﬂuoride and centrifuged (12000g, 5min,
4 C) to eliminate mitochondria. The supernatant was
layered onto a 5ml linear sucrose gradient (15–40%
sucrose [w/v] supplemented with 10mM Tris–HCl, pH
7.5, 140mM NaCl, 1.5mM MgCl2, 10mM dithiothreitol,
100mg/ml cycloheximide and 0.5mg/ml heparin) and
centrifuged in a SW50.1Ti rotor (Beckman) for 1h
40min at 140000g and at 4 C, without brake. Fractions
of 300ml were collected and digested with 100mg pro-
teinase K in 1% SDS and 10mM EDTA (30min, 37 C).
RNAs were then recovered by phenol-chloroform-isoamyl
alcohol extraction, followed by ethanol precipitation.
Finally, the fractions containing the mRNA, were pre-
cipitated with 2M LiCl on ice at 4 C overnight. After
centrifugation (12000g, 15min at 4 C), pellets were
washed with 70% ethanol pre-stored at –20 C, air dried
and resuspended in appropriate volumes of RNAse-free
water.
Total RNA was extracted using the TriZol reagent
protocol (Invitrogen). After DNAse treatment (DNA
free, Ambion) and quantiﬁcation, reverse transcription
was done with 2mg of total RNA using the First strand
cDNA Synthesis kit (Invitrogen) and random hexamers.
The resulting cDNA fragments were PCR ampliﬁed using
three primers allowing simultaneous ampliﬁcation of the
three diﬀerent mRNA species, i.e. spliced on the ﬁrst 30SS,
spliced on the second 30SS and unspliced (i.e. primers RT-
CMV-F, RT-LucR-R and RT-LucF-R for the luciferases
sequences or RT-CMV-F, RT-LC-R and RT-HC-R for
the antibody’s sequences). PCR products were loaded on
a 2% agarose gel and visualized using SYBR Safe DNA
gel staining (Invitrogen). Control reactions were per-
formed using b-actin control primers supplied in the
Superscript III RT kit (Invitrogen). Cryptic splice sites
were identiﬁed after cloning of the corresponding cDNA
fragments puriﬁed from agarose into the pCR4-TOPO
(Invitrogen), and sequencing with appropriate primers
(T3 and T7). Alignment of the resulting sequences with
the cDNA wild-type sequence allowed identiﬁcation of
aberrant splicing events. Corresponding cryptic splice
sites were inactivated by inserting point mutations using
the Quikchange site directed mutagenesis kit (Stratagene)
according to the manufacturer’s instructions with primers
couples listed from QKSC1 -F/-R to QKSC5 -F/-R.
Detection of secreted anti-N-VEGF antibody in the
culture supernatants
Microtiter plates were coated overnight at 25 C with
1mg/ml of recombinant N-VEGF diluted in phosphate
buﬀered saline (PBS). After three washes with 250mlo f
washing solution (PBS/0.05% Tween 20), plates were
blocked with PBS containing 2% (w/v) skimmed milk
for 2h at 25 C and washed three times. Cell-free super-
natants (diﬀerent dilutions) were incubated for 2h at
25 C. After extensive washing with PBS/T, the detection
antibody (i.e. goat anti-mouse IgG, HRP conjugated;
Promega) was diluted at 166ng/ml in PBS/T and
incubated for 2h at 25 C. Further washes were followed
by the addition of 100ml of TMB substrate solution (BD
OptEIA) and the reaction proceeded at 25 C in the dark
for up to 30min. The reaction was then stopped by the
addition of 50mlo f2 NH 2SO4 and the OD450 was
measured immediately using a microplate reader
(UVM340, Asys). Each experiment was repeated at least
three times. Graphs represent the amount of secreted
antibody for each mutant transfected relatively to the
amount secreted with the pA1 vector for transient
transfection experiments and relatively to the amount
secreted with the pCE-s vector for stable transfection
experiments. Errors bars represent standard deviation
and asterisks depict statistically signiﬁcant diﬀerences
compared to pA1 or pCE-s (**P<0.01 and *P<0.05,
ANOVA test).
RESULTS AND DISCUSSION
The aim of this study was to evaluate if alternative splicing
could be a suitable mechanism to generate diﬀerent ratios
of expressed recombinant proteins from a bicistronic
vector.
Evaluation of the eﬃciency of alternative splicing as a
bicistronic mode of expression
In a ﬁrst set of experiments, we wanted to test whether
alternative splicing could lead to the co-expression of two
proteins encoded by two cistrons in the same vector. For
that purpose, we ﬁrst elaborated a plasmid, called V1,
comprising a complete intron in the 50-UTR and an
additional consensus acceptor splice site (30SS) between
the two cistrons (Figure 1A). The intron is constituted
by consensus elements: a donor splice site (50SS), a
branch point, a pyrimidine tract and a 30SS. The construc-
tion was carried out with the Renilla Luciferase (Luc R)
and the Fireﬂy Luciferase (Luc F) as reporter genes.
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through their enzymatic activities, we wanted to evaluate
their respective concentrations by western blotting. For
this goal, we fused the HA tag to their amino-terminal
ends. Consequently, we replaced their original start
codon by a consensus AUG leading to a very similar
initiation of translation (Figure 1A). Theoretically,
transcription of the expression cassette can be followed
by two distinct types of splicing events (resulting from
the use of either the ﬁrst or the second 30SS) thus
generating a ﬁrst mature mRNA allowing Luc R
expression (m1) and a second mRNA encoding Luc F
(m2); whereas a third possibility could be generation of
the unspliced mRNA (m-us) (Figure 1A).
A western blot analysis performed with lysates of CHO
cells transiently transfected with the V1 plasmid revealed
that the two luciferases were detected but HA-LucF
(61kDa) was much more expressed than HA-LucR
(37kDa) (Figure 1B). Our interpretation was that the
second 30SS was predominantly used by the splicing
machinery compared with the ﬁrst one. Repeated experi-
ments also indicated that this ratio was very constant.
Modulation of the ratio between the two luciferases
In order to control the ratio between the two diﬀerent
mRNAs (and consequently the expression of the two
luciferases), our strategy was to weaken eﬃciency of
the second 30SS by a directed mutagenesis approach.
The  3,  5 and  11 positions of the consensus
sequence (Figure 2A) were selected for mutagenesis for
the following reasons: the  3 and  5 positions are the
most conserved (apart the absolute AG) and the  11 is
central in the polypyrimidine tract and could be changed
into purines. All mutated constructs (53 mutants obtained
out of the 64 possibilities) were tested for transient
transfection in CHO cells followed by western blot
analysis. Results revealed a large panel of Luc F/Luc R
ratios between the diﬀerent mutants. From these data,
eight mutants that were representative of the whole
range of expression ratio possibilities were chosen for
further experiments. These mutants, whose second 30SS
sequences are provided in Figure 2A, were called V2 to
V9. When used to transfect CHO cells, the diﬀerent
constructs generated important variations in the relative
expression of the two luciferases. This was evaluated by
measuring their enzymatic activities (Supplementary
Figure S1). Since the speciﬁc activities of the two
luciferases are not clearly established, we also determined
their expression by western blotting (Figure 2B). Diﬀerent
ratios between HA-LucF and HA-LucR quantities can be
observed from a large majority of HA-LucF to a large
majority of HA-LucR and including intermediate ratios
(e.g. ratio close to 1:1). In agreement with the proteins
expression pattern, semi-quantitative-competitive reverse
transcriptase (RT) PCR analyses of the diﬀerent mRNA
species of the same samples revealed an increased amount
of RNA spliced on the ﬁrst 30SS (m1, Luc R) and a
decrease in the amount of RNA spliced on the second
30SS (m2, Luc F) from mutants V2 to V9 (Figure 2C).
Additionally, this RT–PCR analysis also showed that a
signiﬁcant part of the mRNAs were not spliced (‘m-us’
band). This mRNA could potentially be translated to
generate HA-LucR. It was also interesting to point out
the presence of additional PCR products distinct from
the three described earlier. After cloning and sequencing
of these bands, two cryptic 50SS within the Luc R sequence
were identiﬁed and it is worth noting that they were not
predicted as putative splice sites in silico.
To assess if this alternative splicing mechanism was
comparable among cells lines of diﬀerent origins, the set
of plasmids was tested, in parallel, in CHO (hamster),
HeLa (human) and NIH-3T3 cells (mouse). Results
clearly showed that all three cell types presented similar
patterns of expression ratios between the two luciferases
(Figure 2D). Taken together, these results tend to indicate
that (i) the system developed here allows simultaneous
expression of two proteins, (ii) easily permits the
modulation of the ratio between the two proteins and
(iii) could be used in various cell types with equal
eﬃciency.
Expression of the two chains of an antibody
After validation of the vector’s functionality with two
reporter genes, the construction was used to express
a particular heteromultimeric protein consisting in an
equimolar ratio of two polypeptides, i.e. an antibody.
B V1 Ctrl
Luc R
Luc F
A
m-us
0.5 kb
(A)n
Luc F
(A)n
Luc R
(A)n
Luc R
m1
m2
pCMV Luc R Luc F PolyA
Intron
2nd 3′SS
pV1
1st 3′SS 5′SS
Figure 1. Development of a bicistronic vector based on alternative
splicing. (A) Schematic representation of the bicistronic vector based on
alternative splicing (pV1) and the corresponding matures mRNAs. The
two cistrons consist of the HA-tagged Renilla Luciferase (Luc R) and
Fireﬂy Luciferase (Luc F). m1 corresponds to mRNA spliced on the
ﬁrst 30SS leading to expression of Luc R, m2 corresponds to mRNA
spliced on the second 30SS leading to expression Luc F and m-us
corresponds to unspliced mRNA. (B) An anti-HA antibody was used
to perform western blot analysis on protein extracts from pV1 transiently
transfected CHO cells. The upper band (61kDa) corresponds to
HA-LucF (second cistron) and the lower band (37kDa) to HA-LucR
(ﬁrst cistron). Control (Ctrl) corresponds to mock-transfected cells.
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LC to HC is crucial for correct antibodies folding and
assembly (2). This ratio also inﬂuences the amount of
functional secreted antibodies. The main problem is that
the optimum ratio depends on the sequence of the
antibodies, the cell type used for expression and whether
production is performed in a stable or transient context
(4,5,13). Consequently, for each antibody to be produced
in a particular condition, the optimum ratio should be
established. Furthermore, this ratio should be stable,
especially when cell lines are created. For these reasons,
the system developed in this study could be suitable for the
expression of recombinant antibodies because of its
adaptability. Indeed, a panel of mutants generating
various expression ratios between the two chains can be
easily created, thus allowing identiﬁcation of the best
construct for any given antibody, in any cell type chosen
and in any condition.
To test the system, we chose a home-made monoclonal
antibody directed against human N-VEGF, an intra-
cellular protein that results from the cleavage of the
L-VEGF precursor that also generates the secreted
VEGF-A molecule (14) (Figure 3A). The cDNAs
encoding the two chains of this antibody were cloned and
sequenced. The LC and HC cDNAs were sub-cloned in the
bicistronic vector comprising the consensus sequences
for the diﬀerent splice sites, respectively as the ﬁrst and
second cistron, leading to the pA1 construct (Figure 3B).
A western blot analysis performed on a pA1 transfected
CHO lysate showed that only free LC was detectable
(data not shown). This indicated that, in this case,
expression of the ﬁrst cistron was higher than expression
of the second cistron, contrary to what was observed
with the pV1 construct. In agreement with knowledge
in the ﬁeld of alternative splicing mechanisms (8), this
change in preferential 30SS usage could be explained by
the presence of putative regulatory sequences like ESE
or ESS that generally lie within the coding regions. It
may thus be explainable that replacing HA-LucR by
the LC of an antibody may have such an eﬀect on the
splicing pattern.
In order to modulate the expression ratio between
the LCs and HCs, we then chose to mutate the ﬁrst
acceptor site.
Elimination of cryptic splice sites
Because we had to weaken the strength of the ﬁrst 30SS, a
prerequisite was to identify putative cryptic 30SS within
the sequence of the LC encoding cistron. As seen with
the study on luciferases, such sites can be used by the
splicing machinery and thus generate aberrant splicing
events that could potentially lead to the expression of
truncated proteins (Supplementary Figure S2A). In
order to identify these cryptic splice sites, an RT–PCR
analysis was performed on mRNAs extracted from pA1
transfected CHO cells. As expected, this analysis revealed
the presence of the m1 transcript (spliced on the ﬁrst 30SS
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Figure 2. Mutations in the sequence of the second 30SS allows eﬃcient modulation of the expression ratio between the two luciferases. (A) Mutants
of the second 30SS listed from V1 to V9 and their corresponding sequences. V1 corresponds to the consensus splice site sequence. Mutated bases are
bolded and the dinucleotide corresponding to the 30 border of the splice site is underlined. The ﬁrst dinucleotide of exon 2 is in italic. Positions  3,
 5 and  11 that are chosen to be mutated are indicated under the V1 sequence. (B) Western blot analysis on protein extracts from CHO cells
transiently transfected with the 30SS mutants listed in Figure 2A. Ctrl corresponds to mock-transfected cells. In the lower panel, densitometric data
from western blot X-ray ﬁlms are used for graphical representation of the Luc F/Luc R ratio. (C) RT–PCR analysis on mRNAs extracted from CHO
cells transiently transfected with the 30SS mutants pV1 to pV9. Competitive PCR ampliﬁcation was performed using a forward primer hybridizing
upstream the intron 50SS and two reverse primers hybridizing from bases 186 to 206 within the Luc R ORF and from bases 133 to 152 within the
Luc F ORF, thus allowing simultaneous detection of the three mRNA species: m-us, m1 and m2. (D) Graphical representation of densitometric data
calculating Luc F/Luc R expression ratios obtained with the diﬀerent constructs in CHO, HeLa and NIH-3T3 cell lines.
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m2 transcript (spliced on the second 30SS) (Supplementary
Figure S2B). However, several other species of inter-
mediate sizes were detected, most of them quite intense.
This tends to indicate that many abnormal splicing events
frequently occurred, generating an important pool of mis-
spliced transcripts. After cloning and sequencing of
corresponding cDNAs, several cryptic splice sites were
identiﬁed. Most of them were 30SS but we also identiﬁed
cryptic 50SS. One of them, a donor site located three bases
upstream the LC STOP codon, was found to splice with
the second constitutive acceptor site in almost 90% of the
atypical spliced transcripts. Surprisingly, many of the
identiﬁed sites were 30SS despite the lack of a clearly
deﬁned pyrimidine tract. The sites were mutated with
respect to the amino-acid sequence of the encoded
polypeptide. As new cryptic splice sites may be activated
if a mutation alters or removes a genuine nearby site, the
experiment was repeated three times after each round of
identiﬁcation/mutation, and we clearly observed that
aberrant splicing was considerably lowered after each
step (data not shown).
Since we planed to mutate the ﬁrst constitutive 30SS to
weaken its eﬃciency, it was of importance to test the
presence of remaining cryptic splice sites under conditions
of poor eﬃcient intron 30SS. In this goal, two mutants
corresponding to variants V5 and V9 were generated.
As expected, the analysis revealed activation of new
cryptic splice sites which all were corrected. Finally, 10
30SS and 5 50SS were identiﬁed and mutated, as shown
in Figure 3C.
Analysis of the mRNA proﬁle of pA1 transfected CHO
cells (that contained the LC mutated for all identiﬁed
cryptic splice sites) revealed two major products
corresponding to the expected spliced mRNAs and no
extra bands. In these conditions, the m1 species was
clearly more abundant than the m2 mRNA
(Supplementary Figure S2C).
Modiﬁcation of the ratio between the two chains of the
antibody
In order to modify the ratio between the two diﬀerent
mRNAs (and consequently control the relative
expression of the LCs and HCs) we mutated the
sequence of the ﬁrst acceptor splice site. The sequences
chosen were those of the 8 mutants described earlier and
mentioned as V2 to V9. These mutants (called A2 to A9)
were used to transfect CHO and HEK293T cells, two cell
types typically used for recombinant antibody expression
because of easy adaptation to suspension and serum-free
culture conditions, high transfection eﬃciency and
high production rates (15). As described earlier with
the luciferases system, mutants of the acceptor splice
sites allowed eﬃcient modulation and displayed a wide
range of LC to HC mRNA ratios both in CHO (Figure
4A) and HEK cells (Figure 4C). As expected, these
variations directly correlated with the amount of func-
tional secreted antibody (determined by antigen-coated
ELISA) in both cells types as shown in Figures 4B and
4D. Indeed, for CHO cells, mutants A6 and A8 showed
signiﬁcant increase in the level of secreted antibodies
compared to A1 (Figure 4B), mutant A8 being the best
producer with a 4-fold increase. In HEK cells, the same
two mutants also led to the best productivity allowing a
2-fold increase in the level of secreted antibodies. These
results are in accordance with western blot analysis of
secreted antibodies (Supplementary Figure S3A). As
controls, we demonstrated that LC alone could be
N-VEGF
Signal
peptide VEGF
L-VEGF
B
C
A
pCMV LC HC PolyA
Intron 3′SS
0.5 kb
pA1
T
ATG AAG TTG CCT GTT AGG CTG TTG GTG CTG ATG TTC TGG ATT CCT GCT TCC AGC AGT ---- Variable region ---- CTA GAA ---
MKLPVRLLVLMFWIPASSS LE
TC G A TCC A A
--- CCA GAT AGG TTC --- AAA CGG GCT GAT GCT GCA CCA ACT GTA TCC ATC TTC CCA CCA TCC AGT GAG CAG TTA ACA TCT GGA GGT
PDRF KRADAAPTVSIFPPSSEQLTSGG
GCC TCA GTC GTG TGC TTC TTG AAC AAC TTC TAC CCC AAA GAC ATC AAT GTC AAG TGG AAG ATT GAT GGC AGT GAA CGA CAA AAT GGC
ASVVCFLNNFYPKDINVKWKIDGSERQNG
GTC CTG AAC AGT TGG ACT GAT CAG GAC AGC AAA GAC AGC ACC TAC AGC ATG AGC AGC ACC CTC ACG TTG ACC AAG GAC GAG TAT GAA
VLNSWTDQDSKDSTYSMSSTLTLTKDEYE
CA CC A C A
CGA CAT AAC AGC TAT ACA TGT GAG GCC ACT CAC AAG ACA TCT ACT TCA CCC ATT GTC AAG AGC TTC AAC AGG AAT GAG TGT TAG
RHNSYTCEATHKTSTSPIVKSFNRNEC*
Figure 3. Use of the bicistronic vector for production of a murine recombinant antibody anti-N-VEGF. (A) Schematic representation of the
precursor L-VEGF molecule which cleavage generates secreted VEGF-A and intracellular N-VEGF. (B) Schematic representation of the bicistronic
vector constructed for antibody anti-N-VEGF expression (pA1). The LC was cloned as the ﬁrst cistron and the HC as the second cistron.
(C) Sequence of the anti-N-VEGF LC constant region and cryptic splice sites of the variable region. The signal peptide is showed in the black-
lined box, followed by the variable region of the LC. The arrow delimits the variable region (upstream) and the constant region (downstream).
Identiﬁed cryptic 50 (GT) and 30SS (AG) are underlined and mutations are represented in bold above the sequence.
e134 Nucleic Acids Research, 2009,Vol.37, No. 20 PAGE 6 OF 10eﬃciently secreted and form dimers, whereas HC alone
could not be secreted as expected (16,17) (Supplementary
Figure S3B). Obviously, we conﬁrmed that single chains
were not able to recognize the antigen in the ELISA test
(data not shown).
In conditions of transient transfection, it is not evident
to determine an optimal ratio between the LC and HC
encoding mRNAs since mutants A6 and A8 gave the
best results and present reciprocal mRNA ratios. How
inverse ratios could provide a comparable production
of antibody is not really understood but similar results
were provided by others (4). However, it is clear
that extreme imbalanced ratios were deleterious for
antibody production. Most of the mutants showed the
same eﬃciency when compared between CHO and
HEK293T. One major diﬀerence should be underlined:
the unspliced form was more present in HEK293T than
in CHO cells. This could be interpreted as a less eﬃcient
recognition of the 50SS in HEK293T cells. This fact could
be of general importance since most expression vectors
possess the same kind of intron in their 50-UTR. Thus, it
could be of interest to optimize the eﬃciency of the 50SS,
especially for its use in these cells.
Study of mRNA species engaged in polysomes
Since a signiﬁcant part of the mRNAs was unspliced,
especially in HEK293T transfected cells, we tried to
evaluate the translation eﬃciency of this species that
have a larger 50-UTR than spliced mRNAs. This study
was performed by polysome-associated RNAs assay
(Figure 5A). For this purpose, HEK293T cells were
transfected with the A6 mutant and polysome fractio-
nation was done. Diﬀerent fractions from the sucrose
gradient were collected and associated mRNAs corres-
ponding to species from free mRNAs to mRNAs associa-
ted with poly-ribosomes were isolated (Figure 5B).
Fractions were pooled into four distinct groups and
analyzed by RT–PCR to detect the diﬀerent species. As
shown in Figure 5C, mRNA spliced on the ﬁrst 30SS,
mRNA spliced on the second 30SS but also unspliced
mRNA are present in all the fractions. This indicates
that the three species can be eﬃciently translated
(fractions 3 and 4), including unspliced mRNA that
generates the LC. It could be noticed that the ratio
between unspliced/spliced mRNAs is lower in translated
mRNAs (mostly fractions 3 and 4) than in untranslated
mRNAs (fraction 1) or total RNA (Figure 5C, lane T).
This reinforces a previous conclusion about the need
to improve eﬃciency of the intron 50SS recognition
since, even if the unspliced form can be partially
translated, it represents a loss in the eﬃciency of the
total mRNA to produce full antibodies. However, an
important part of transcribed mRNAs remained in
fractions 1 and 2 suggesting that translational machinery
may be saturated in these cell culture conditions and that
increasing the cells translational capacity could be a way
to improve their productivity.
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Figure 4. Eﬀect of the diﬀerent 30SS mutants on expression eﬃciency in transiently transfected CHO or HEK293T cells lines. CHO (A and B) and
HEK293T (C and D) cells were transfected with diﬀerent mutants of the ﬁrst 30SS from pA2 to pA9. (A and C) upper panels: RT–PCR analysis on
mRNAs. Competitive PCR ampliﬁcation was performed using a forward primer hybridizing upstream the intron 50SS and two reverse primers
hybridizing from bases 419 to 458 of the LC ORF and from bases 303 to 324 of the HC ORF. (A and C) lower panels: western blot analysis on
protein extracts from CHO (A) and HEK293T (C) cells transfected with the diﬀerent 30SS mutants. Anti b-actin was used to control protein loading.
(B and D) Amount of functional antibodies secreted by CHO (B) and HEK293T (D) cells transfected with the diﬀerent mutants pA2 to pA9 in
comparison to pA1 containing the consensus sequences for all splice sites, determined by antigen speciﬁc ELISA. Data are presented as
means SEM. Statistical signiﬁcance was evaluated using one-way ANOVA test. *P<0.05, **P<0.01.
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other constructs in stably transfected cells
As many processes for recombinant antibody production
involve the use of stable cell lines, we ﬁnally wanted to
investigate if the vectors based on alternative splicing
could be successfully utilized in such conditions.
Expression cassettes including VEGF IRES-A and the
gene coding for neomycin were cloned downstream of
the HC in pA1 to pA9 constructs (Figure 6A) to allow
selection of the stable transfectants under G418 treatment.
Two additional constructs were generated in order to
compare, in this context, the vectors based on alternative
splicing to other types of vectors, classically used for
recombinant antibody production, i.e. a vector with
an IRES and a vector with two diﬀerent promoters
(Figure 6A). For the vector containing the IRES
between the two cistrons, we chose the EMCV IRES,
which is one of the most eﬃcient IRES in a great
number of cell types and therefore the most commonly
used for expression of recombinant antibodies (18,19).
For the vector in which transcription of the HC is under
a separate promoter, we chose the EF1a promoter which
was successfully used in vectors for IgG mammalian
expression (20).
RT–PCR analysis performed on mRNAs extracted
from stable pools of cells transfected with vectors pA1-s
to pA9-s showed a clear excess in the LC mRNA
from mutants A1-s to A5-s, an excess of HC mRNA for
mutants A7-s and A9-s and a more balanced ratio for
mutants A6-s and A8-s (Figure 6B).
In order to test the stability of the splicing eﬃciency
throughout the cell divisions, a RT–PCR experiment
was performed on mRNAs extracted from cells at
passages 2, 5, 10 and 20. The proﬁles obtained for three
representative mutants (A4, A7 and A8) clearly indicate
that the ratio between the diﬀerent mRNA species was
stable throughout passages (Supplementary Figure S4).
As shown in Figure 6C, mutants leading to the best
productivity were mutants A7-s and A9-s, indicating
that, in a stable context, an excess for HC mRNA
tended to be more favourable for antibody productivity.
Previous results have also reported that an excess of HC
mRNA or polypeptide can lead to a more eﬃcient IgG
production in HEK or CHO cells both in transient (4,5)
or stable transfection (3). The fact that the best producers
were diﬀerent in a transient versus a stable context might
be interpreted with potential diﬀerences in the splicing
eﬃciency in the two contexts, thus leading to slight
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transfectants and comparison to other constructs. (A) Schematic
representation of the diﬀerent vectors used to generate stable pools of
CHO transfectants: bicistronic vectors based on alternative splicing
(pAx-s), IRES-containing bicistronic vector (pCI-s) and double-
promoter vector (pCE-s). (B) RT–PCR analysis of mRNAs extracted
from CHO cells stably transfected with the diﬀerent 30SS mutants
pA1-s to pA9-s. (C) Amount of functional antibodies secreted by
pools of CHO cells stably transfected with mutants pA1-s to pA9-s
in comparison to the IRES-containing bicistronic vector (pCI-s) and
the bigenic vector (pCE-s). Data are presented as means SEM.
Statistical signiﬁcance was evaluated using one-way ANOVA test.
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Figure 5. Study of mRNA species engaged in polysomes. (A) Schematic
representation of polysomal and free mRNAs distribution after sucrose
density gradient RNA fractionation of pA6 transfected CHO cells.
(B) RNAs puriﬁed from each fraction, collected from top to bottom of
the sucrose density gradient, were visualised on agarose gel by SyBRgreen
staining. The fractions were pooled in four samples representing the
diﬀerent stages of mRNAs commitment in translation. (C) RT–PCR
analysis was performed on mRNAs extracted from the four samples
obtained after polysomes fractionation. To exclude any DNA
contamination,PCRreactions wereperformedonthefourRNAfractions
lacking the Reverse Transcriptase step ( RT). The control T corresponds
to the RT–PCR process with total RNA, i.e. before polysomes
fractionation, and Ctrl to PCR ampliﬁcation with pA1 as the matrix.
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be, as it has been described by Schlatter et al. (4) that
the optimal ratio between the two mRNAs is diﬀerent
depending on whether production is performed in
transiently or stably transfected cells.
Figure 6C also showed that, compared to the two
‘reference’ constructs, pCE-s and pCI-s, some mutants
of the vector based on alternative splicing, mutants A7-s
to A9-s, allow secretion of a greater amount of functional
antibodies. This clearly indicates that vectors based on
alternative splicing can be an interesting alternative to
conventionally used vectors. Moreover, only a restricted
number of 30SS mutants have been tested here. One can
imagine that other mutations might allow to control more
tightly the ratio between the two chains and thus permit
even greater antibody productivity.
In accordance to studies performed with other
antibodies sequences in diﬀerent expression systems, our
results emphasize the fact that the optimum ratio for
maximal antibody productivity is poorly predictable.
The system developed in this study overcomes this
problem by allowing rapid screening of several mutants,
generating diﬀerent possibilities of ratios between the two
chains. In addition, our results indicate that if an excess of
HC encoding mRNA is favourable for antibody secretion
when expressed after permanent transfection, it seems
that no clear rule can be established for transient
transfection. In this last case, an empirical approach
consisting of testing several possibilities remains
appropriate. However, ﬁnding the best combination for
each antibody to be expressed in a chosen cell type
could be easily achieved. Moreover, this method,
involving the use of only one plasmid, seems more
reproducible than co-transfection of two plasmids in
various ratios (4) because this technique could easily be
biased by (i) various transfection eﬃciencies in transient
experiments, (ii) extrapolation for stable transfections and
(iii) chromosomal insertion sites of the two plasmids
because these sites have a major eﬀect on expression
eﬃciency (21). Using a single vector with two independent
genes generates invariable expression ratio between the
two proteins but also (i) two identical promoters may
lead to recombination events in the case of stable
expression, (ii) diﬀerent promoters could be perturbed
by transcriptionnal interference or suppression events
(1). In addition, plasmids with the EMCV IRES have
also been successfully used to generate diﬀerent mutants
expressing various ratios of HC to LC (5). However,
Mizuguchi et al. (22) showed that the translation eﬃciency
of the IRES can only reach maximum 60% of the cap-
dependent translation eﬃciency of the ﬁrst cistron. On the
opposite, our system clearly allows a larger panel of ratios
from 10:1 to 1:10, thus permitting extended possibilities
compared to IRES-driven systems but also to 2A peptide-
containing systems that only provide a unique ratio (23).
CONCLUSION
During the establishment of the Alternative Splicing-
based Bicistronic (ASB) vector we have provided
information concerning the presence of cryptic splice
sites that could be usefully integrated for classical
vectors that contain an intron in their 50-UTR. In the
particular example of antibody production, this work
would facilitate further production of other murine
antibodies, since the majority of the identiﬁed cryptic
splice sites (11/15 identiﬁed sites) are located in the
sequence that encodes the constant region of the LC.
Indeed, simple cloning of diﬀerent variable regions in
frame with the previously mutated constant region can
be done allowing an easier and faster research for
additional cryptic splice sites and further optimize
antibodies production eﬃciency.
We provide here a novel system to elaborate bicistronic
vectors that present several advantages in addition to its
main interest which is the possibility to control the ratio of
two expressed proteins: (i) the expression and the ratio are
stable and very similar for several cell lines for both
transient and stable transfection (ii) the vector is small
and easy to manipulate, (iii) the vector could be easily
adapted to study ESE or ESS.
Further modiﬁcations could be performed in order to
optimize the production yield. Finally this system might
be easily adapted for expression of several heteromeric
proteins for which the ratio between two subunits has to
be tuned or for expression of two distinct proteins with
synergistic eﬀects at variable ratios, e.g. in gene therapy
experiments.
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